Mortality Rates in INOCA and MINOCA
MINOCA carries a composite mortality or nonfatal MI rate of approximately 4.6% in contemporary analyses, which is more than double that of patients without atherosclerotic cardiovascular disease (2.2%) but approximately one-third that of MI with obstructive coronary artery disease (14.3%) 1.
Short-Term Mortality
MINOCA
- In-hospital mortality: 0.8-1.5% 2, 3
- Significantly lower than MI with obstructive CAD (2.7-6.2%)
- The prognosis is not benign despite the absence of obstructive disease 1
Key Prognostic Caveat
The 5-year mortality hazard risk for MINOCA patients is 1.93 times higher than those with MI-CAD in STEMI presentations 1. This counterintuitive finding emphasizes that MINOCA mimicker diagnoses (Takotsubo, myocarditis) had outcomes similar to obstructive MI-CAD patients, underscoring the critical need to identify the underlying cause at presentation.
Long-Term Mortality
MINOCA Annual Mortality Rates
- Overall annual mortality: 2.0-2.2% (95% CI: 1.5-2.7%) 4, 2
- 2-year all-cause mortality: 4.9% 5
- Non-cardiovascular deaths predominate (4.5% vs 3.6% cardiovascular deaths)
- 5-year mortality: 10.9% 2
- 10-year mortality: 20%, primarily from non-cardiovascular causes 6
Comparative Context
The long-term mortality after MINOCA is significantly lower than MI with obstructive CAD (relative risk: 0.60,95% CI: 0.46-0.78) 4, but remains 4.64 times higher than age and sex-matched patients without cardiovascular disease (95% CI: 3.54-6.10) 5.
Critical Prognostic Stratification by CMR Findings
Cardiac magnetic resonance imaging provides crucial risk stratification 1:
- Normal CMR: 3.5% 10-year MACE rate
- Acute myocardial infarction pattern: 47% MACE rate
- Myocarditis: 24% MACE rate
- Non-ischemic cardiomyopathy: 50% MACE rate
This dramatic variation in outcomes based on underlying etiology explains why systematic diagnostic evaluation is essential rather than treating MINOCA as a single entity.
Predictors of Adverse Outcomes
Independent Mortality Predictors
- Reduced ejection fraction (p ≤ 0.0001) 4
- Non-obstructive CAD present (vs completely normal arteries) (p = 0.004) 4
- ST depression on admission ECG (p = 0.016) 4
- Advanced age (p < 0.001) 7
- Elevated creatinine (p < 0.001) 7
- Functional capacity (exercise stress test duration) 6
Important Clinical Distinction
Patients with completely normal coronary angiograms (36.8% of MINOCA) have even better outcomes:
- 1-year death/re-MI rate: 3.9% vs 6.1% in those with <50% stenosis 2
- However, these patients receive even lower rates of evidence-based medications, representing a significant treatment gap
INOCA-Specific Mortality Data
While the 2024 ESC guidelines 8 emphasize that INOCA/ANOCA represents a significant clinical entity requiring systematic evaluation, specific long-term mortality data for chronic INOCA (as distinct from acute MINOCA) is less well-defined in the provided evidence. The guidelines stress that multiple mechanisms frequently contribute to ischemia, and the presence of severe stenosis does not preclude other considerations like coronary microvascular dysfunction or vasospasm.
Critical Clinical Pitfalls
Therapeutic nihilism: Despite lower mortality than obstructive MI-CAD, MINOCA patients have significantly higher cardiovascular rehospitalization rates (33.3% vs 21.5%) 3 and receive inadequate secondary prevention
Undertreatment: Evidence-based medication rates at 6 months are significantly lower in MINOCA patients, particularly those with normal angiograms 2
Missed diagnoses: Failure to identify underlying mechanisms leads to worse outcomes, as MINOCA mimickers have mortality rates similar to obstructive MI-CAD 1
Non-cardiovascular mortality predominates in long-term follow-up, suggesting these patients have significant comorbidities requiring comprehensive management 5